SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to...
Clinical Trial
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and...
IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
SAINT LAURENT, Quebec, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today provided an update...
Cassava Sciences Announces Initiation of an Open-label Extension Study
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100...
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023LEXINGTON, Mass., Oct. 13, 2022...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel...
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting (NASPGHAN) – Earlier treatment...
Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
- Stride velocity 95th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and...
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Topline results for PATHFNDR-1 study expected in Q3 2023SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:...
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19%...
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,...
Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait
Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy MonthNEWTOWN,...
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform,...